Oncomyc-NG

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameOncomyc-NG
Drug Alias NameResten-MPResten-NGAVI-4126AVI-2221
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionMyc proto-oncogene protein modulators
TargetsMyc proto-oncogene protein
Therapy Area/IndicationsCoronary RestenosisCoronary Artery DiseaseNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSarepta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSarepta Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCoronary RestenosisCoronary Artery DiseaseNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A